Ponatinib
Ponatinib
Ponatinib (pronounced poh-nuh-tih-nib) is a type of tyrosine kinase inhibitor used in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Etymology
The name "Ponatinib" is derived from the chemical name of the drug, which is 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide. The "Ponat" part of the name is a reference to the chemical structure of the drug, while the "-inib" suffix is common in drugs that inhibit specific proteins or enzymes.
Usage
Ponatinib is used to treat adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to or cannot tolerate other treatments. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, helping to stop or slow the spread of cancer cells.
Related Terms
- Tyrosine kinase inhibitor: A type of drug that blocks the action of enzymes known as tyrosine kinases, which can stimulate the growth of cancer cells.
- Leukemia: A type of cancer that affects the blood and bone marrow.
- Chronic myeloid leukemia (CML): A type of cancer that starts in certain blood-forming cells of the bone marrow.
- Philadelphia chromosome: An abnormality of chromosome 22 found in most patients with chronic myeloid leukemia.
- Acute lymphoblastic leukemia (ALL): A type of cancer in which the bone marrow makes too many immature lymphocytes, a type of white blood cell.
External links
- Medical encyclopedia article on Ponatinib
- Wikipedia's article - Ponatinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski